'Outstanding' Long-Term T-DM1 Data in Early Breast Cancer

One year of adjuvant T-DM1 demonstrated high 5-year invasive disease-free survival rates in patients with stage I HER2-positive breast cancer, researchers reported.
Medscape Medical News